The Asian Age - - Money -

Natco's part­ner My­lan has an­nounced that it has re­ceived ap­proval for Copax­one 40mg and 20mg both. It is the first generic to re­ceive ap­proval for 40mg and sec­ond generic for 20 mg. The com­pany will launch the generic imme­nently. Copax­one is in­di­cated for the treat­ment of pa­tients with re­laps­ing forms of mul­ti­ple sclero­sis (MS). The bro­ker­age be­lieves that Natco could be the only generic in the mar­ket for 40mg for the next six months. The two near­est play­ers are San­doz and Dr Reddy’s. San­doz has got a warn­ing let­ter on the man­u­fac­tur­ing plant, which will likely de­lay ap­proval till next year. Ac­cord­ing to Jef­feries, Natco’s strong R&D team, com­plex spe­cialty fo­cus pipe­line and lack of sig­nif­i­cant FDA is­sues makes it one of the best placed In­dian pharma com­pa­nies. Un­like peers, it is not im­pacted by price ero­sion in its base busi­ness. Its strat­egy of a niche US fo­cus and em­pha­sis on In­dia and emerg­ing markets should lead to bet­ter re­turns.

Broking firm: Jef­feries Rat­ing: Buy Clos­ing price: `991.80

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.